

XDEMZY® gives you Might Over Mites™

XDEMZY is here



xdemzy®
(lotilaner ophthalmic
solution) 0.25%

XDEMZY is the first and only FDA-approved treatment for patients troubled with *Demodex* blepharitis, an eyelid disease estimated to impact approximately 25 million eye care patients in the United States.¹⁻³

We invite you to join us and a select group of your peers for one of our *DemodeXperience* discussions! Your host will be Cristos Ifantides, MD, who will discuss the data and clinical results behind XDEMZY.

INDICATIONS AND USAGE

XDEMZY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of *Demodex* blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Please see additional Important Safety Information on next page.

DEMODEXPERIENCE
Demodex blepharitis Dialogues

XDEMZY and the *DemodeXperience*: *Demodex* Blepharitis Dialogues

Epicurean Hotel - Elevage Restaurant
1207 S. Howard Avenue
Tampa, FL 33606
Program ID: 1430
Date: Thursday, June 25, 2026
Time: 6:30 PM ET

Presented by Key Thought Leader:



Cristos Ifantides, MD

Tyson Eye
Fort Myers, FL 33606



Join us at the *DemodeXperience*
to elevate your expertise!

Register at
www.tarsusrsvp.com/index/meeting/1430
Or scan QR code

IMPORTANT SAFETY INFORMATION (cont'd)

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals, Inc. at 1-888-421-4002 or the FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see full Prescribing Information.

Available by prescription only.

For additional information, please see www.xdemvyhcp.com.

References: **1.** XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023. **2.** O'Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of *Demodex* blepharitis. *Clin Ophthalmol.* 2022;16:2979-2987. **3.** Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of *Demodex* blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. *Clin Ophthalmol.* 2022;16:1153-1164.



15440 Laguna Canyon Road, Ste 160, Irvine, CA 92618

© 2025 Tarsus Pharmaceuticals, Inc.

Tarsus, XDEMVY, and the associated logos are registered trademarks and Might Over Mites is a trademark of Tarsus Pharmaceuticals, Inc.

US--2500071 3/25

Our hope is that this *DemodeXperience* will provide the information you need to begin important conversations with your patients about XDEMVY and its compelling approach to treating *Demodex* blepharitis.

If you have any questions or would like additional details about this meeting, please contact me at the information provided below.

We look forward to seeing you there!

Sincerely,

Tarsus Representative:

Jennifer Stastny

Sr. Territory Leader

Cell: (813) 503-5382

Email: jstastny@tarsusrx.com